Cart
sales@molnova.com
Edasalonexent
CAS No. 1204317-86-1
Edasalonexent( CAT-1004 | CAT1004 )
Catalog No. M10746 CAS No. 1204317-86-1
Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 267 | Get Quote |
|
| 50MG | 1224 | Get Quote |
|
| 100MG | 1674 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEdasalonexent
-
NoteResearch use only, not for human use.
-
Brief DescriptionEdasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
-
DescriptionEdasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA); significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever DMD model; Edasalonexent is hydrolyzed by FAAH to release salicylic acid and DHA intracellularly and to suppress activated NF-κB.Other Indication Phase 2 Clinical.
-
In VitroEdasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retrieverduchenne muscular dystrophy (DMD) model.
-
In VivoThe treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury.
-
SynonymsCAT-1004 | CAT1004
-
PathwayApoptosis
-
TargetNF-κB
-
RecptorNF-κB
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1204317-86-1
-
Formula Weight490.688
-
Molecular FormulaC31H42N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 120 mg/mL (244.56 mM)
-
SMILESO=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O
-
Chemical NameN-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Donovan JM, et al. J Clin Pharmacol. 2017 May;57(5):627-639.
2. Vu CB, et al. J Med Chem. 2016 Feb 11;59(3):1217-31.
molnova catalog
related products
-
Galloylpaeoniflorin
Galloylpaeoniflorin may be developed as a cytoprotector against ROS-mediated oxidative stress. Galloylpaeoniflorin is also an inhibtior of NF-κB and DNA cleavage.
-
ABD328
ABD328 (ABD-328) is an orally active, small molecule inhibitor of RANKL and TNF signalling that inhibits inflammation in vivo.
-
EN450
EN450 is a cysteine-responsive covalent molecular gel degrader of targeted NF-κB with antiproliferative and potentially anticancer activity, which acts through a dependence on Cullin E3 ligase and protease, and can be used to study leukemia.
